A Phase I Open-Label Study To Evaluate The Effect Of Multiple Doses Of Azd1775 On The Pharmacokinetics Of Substrates For Cyp3a, Cyp2c19, Cyp1a2 And To
Posted Date: May 15, 2019
- Investigator: Trisha Wise-Draper
- Type of Study: Drug
AstraZeneca D6014C00006
Criteria:
To Be Eligible To Participate In This Study, Patients Must Have Advanced Solid Cancer For Which Ther
Keywords:
Cancer, D6014c00006, Phase I, Solid Tumor
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com